<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9000045</article-id><article-id pub-id-type="doi">10.3390/jcm11071873</article-id><article-id pub-id-type="publisher-id">jcm-11-01873</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">WT1</italic> Gene Mutations, rs16754 Variant, and <italic toggle="yes">WT1</italic> Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Koczkodaj</surname><given-names>Dorota</given-names></name><xref rid="af1-jcm-11-01873" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zmorzy&#x00144;ski</surname><given-names>Szymon</given-names></name><xref rid="af1-jcm-11-01873" ref-type="aff">1</xref><xref rid="c1-jcm-11-01873" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9592-5174</contrib-id><name><surname>Grygalewicz</surname><given-names>Beata</given-names></name><xref rid="af2-jcm-11-01873" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Pie&#x00144;kowska-Grela</surname><given-names>Barbara</given-names></name><xref rid="af2-jcm-11-01873" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0186-3118</contrib-id><name><surname>Styk</surname><given-names>Wojciech</given-names></name><xref rid="af3-jcm-11-01873" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0783-6153</contrib-id><name><surname>Popek-Marciniec</surname><given-names>Sylwia</given-names></name><xref rid="af1-jcm-11-01873" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7591-5887</contrib-id><name><surname>Filip</surname><given-names>Agata Anna</given-names></name><xref rid="af1-jcm-11-01873" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Reikvam</surname><given-names>H&#x000e5;kon</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-11-01873"><label>1</label>Department of Cancer Genetics with Cytogenetic Laboratory, Medical University of Lublin, 20-059 Lublin, Poland; <email>dorotakoczkodaj@umlub.pl</email> (D.K.); <email>sylwia.popek@gmail.com</email> (S.P.-M.); <email>aafilip@hotmail.com</email> (A.A.F.)</aff><aff id="af2-jcm-11-01873"><label>2</label>The Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warszawa, Poland; <email>grygalewicz@yahoo.com</email> (B.G.); <email>barbara.pienkowska-grela@coi.pl</email> (B.P.-G.)</aff><aff id="af3-jcm-11-01873"><label>3</label>Department of Psychology, Institute of Pedagogy and Psychology, Warsaw Management University, 03-772 Warszawa, Poland; <email>wojciech.styk@gmail.com</email></aff><author-notes><corresp id="c1-jcm-11-01873"><label>*</label>Correspondence: <email>s.zmorzynski@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2022</year></pub-date><volume>11</volume><issue>7</issue><elocation-id>1873</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>(1) Background: The aim of our study was the complex assessment of <italic toggle="yes">WT1</italic> variants and their expression in relation to chromosomal changes and molecular prognostic markers in acute myeloid leukemia (AML). It is the first multidimensional study in Polish AML patients; (2) Methods: Bone marrow aspirates of 90 AML patients were used for cell cultures (banding techniques and fluorescence in situ hybridization), and to isolate DNA (<italic toggle="yes">WT1</italic> genotyping, array comparative genomic hybridization), and RNA (<italic toggle="yes">WT1</italic> expression). Peripheral blood samples from 100 healthy blood donors were used to analyze <italic toggle="yes">WT1</italic> rs16754; (3) Results: Allele frequency and distribution of <italic toggle="yes">WT1</italic> variant rs16754 (A;G) did not differ significantly among AML patients and controls. Higher expression of <italic toggle="yes">WT1</italic> gene was observed in AA genotype (of rs16754) in comparison with GA or GG genotypes&#x02014;10,556.7 vs. 25,836.5 copies (<italic toggle="yes">p</italic> = 0.01), respectively. <italic toggle="yes">WT1</italic> mutations were more frequent in AML patients under 65 years of age (<italic toggle="yes">p</italic> &#x0003c; 0.0001) and affected relapse-free survival (RFS). The presence of <italic toggle="yes">NPM1</italic> or <italic toggle="yes">CEBPA</italic> mutations decreased the risk of <italic toggle="yes">WT1</italic> mutation presence, odds ratio (OR) = 0.11, 95% CI 0.02&#x02013;0.46, <italic toggle="yes">p</italic> = 0.002 or OR = 0.05, 95% CI 0.006&#x02013;0.46, <italic toggle="yes">p</italic> = 0.002, respectively. We observed significantly higher <italic toggle="yes">WT1</italic> expression in AML CD34+ vs. CD34&#x02212;, &#x02212;20,985 vs. 8304 (<italic toggle="yes">p</italic> = 0.039), respectively. The difference in <italic toggle="yes">WT1</italic> expression between patients with normal and abnormal karyotype was statistically insignificant; (4) Conclusions: <italic toggle="yes">WT1</italic> gene expression and its rs16754 variant at diagnosis did not affect AML outcome. <italic toggle="yes">WT1</italic> mutation may affect RFS in AML. </p></abstract><kwd-group><kwd>acute myeloid leukemia</kwd><kwd><italic toggle="yes">WT1</italic> gene expression</kwd><kwd><italic toggle="yes">WT1</italic> gene mutation</kwd><kwd>rs16754 variant</kwd><kwd>chromosomal aberrations</kwd><kwd><italic toggle="yes">FLT3</italic> mutation</kwd><kwd><italic toggle="yes">NPM1</italic> mutation</kwd><kwd><italic toggle="yes">CEBPA</italic> mutation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-11-01873"><title>1. Introduction</title><p>Acute myeloid leukemia (AML) affects the function of the hematopoietic system and is a genetically heterogeneous disease at cytogenetic and molecular levels [<xref rid="B1-jcm-11-01873" ref-type="bibr">1</xref>]. AML development includes multistep events associated with point mutations, as well as chromosomal aberrations [<xref rid="B2-jcm-11-01873" ref-type="bibr">2</xref>]. Mutations in genes encoding Wilms tumor 1 (<italic toggle="yes">WT1</italic>), nucleophosmin (<italic toggle="yes">NPM1</italic>), FMS-like tyrosine kinase-3 (<italic toggle="yes">FLT3</italic>), and CCAAT/enhancer-binding protein alpha (<italic toggle="yes">CEBPA</italic>) affect the pathogenesis of AML [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>]. </p><p>The <italic toggle="yes">WT1</italic> gene (<italic toggle="yes">locus</italic> 11p13) encodes a transcription factor that regulates cell growth and differentiation [<xref rid="B4-jcm-11-01873" ref-type="bibr">4</xref>]. It contains 10 exons, of which 4 (7&#x02013;10) encode a DNA-binding domain [<xref rid="B5-jcm-11-01873" ref-type="bibr">5</xref>]. The <italic toggle="yes">WT1</italic> gene may possess both tumor suppressor and oncogenic functions in childhood Wilms tumors and leukemias, respectively [<xref rid="B6-jcm-11-01873" ref-type="bibr">6</xref>]. <italic toggle="yes">WT1</italic> gene mutations are found in 6&#x02013;15% of newly diagnosed AML patients [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>]. Hot spots were described in two exons (7 and 9), in which loss of function mutations can occur [<xref rid="B7-jcm-11-01873" ref-type="bibr">7</xref>]. The alterations of the <italic toggle="yes">WT1</italic> gene are associated with younger age, as well as the coexistence of <italic toggle="yes">FLT3</italic> and <italic toggle="yes">CEBPA</italic> mutations [<xref rid="B7-jcm-11-01873" ref-type="bibr">7</xref>]. The changes in the <italic toggle="yes">WT1</italic> gene sequence may affect its expression [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>]. The role of <italic toggle="yes">WT1</italic> mutations in the pathogenesis of AML remains controversial [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>]. </p><p>Among many variants present in the <italic toggle="yes">WT1</italic> gene, special attention has been paid to the single nucleotide polymorphism rs16754 located in exon 7 (at nucleotide 1297A&#x0003e;G) [<xref rid="B8-jcm-11-01873" ref-type="bibr">8</xref>]. Some studies have suggested that rs16754 can be a negative prognostic factor in AML [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>,<xref rid="B9-jcm-11-01873" ref-type="bibr">9</xref>]. The prognosis in AML is affected adversely by <italic toggle="yes">WT1</italic> gene overexpression [<xref rid="B10-jcm-11-01873" ref-type="bibr">10</xref>,<xref rid="B11-jcm-11-01873" ref-type="bibr">11</xref>]. The WT1 protein shows antiapoptotic activity. Moreover, higher <italic toggle="yes">WT1</italic> expression is associated with lower cell differentiation [<xref rid="B12-jcm-11-01873" ref-type="bibr">12</xref>]. However, the exact role of the <italic toggle="yes">WT1</italic> gene in AML pathogenesis has not been completely revealed. The highest levels of <italic toggle="yes">WT1</italic> expression were found in the M3 AML subgroup (according to French-American-British, FAB, classification) and were linked to a failure of achieving complete remission (CR), shorter overall survival (OS), and shorter progression-free survival [<xref rid="B13-jcm-11-01873" ref-type="bibr">13</xref>,<xref rid="B14-jcm-11-01873" ref-type="bibr">14</xref>]. It is possible that some changes in coding or noncoding regions of the <italic toggle="yes">WT1</italic> gene or some chromosomal aberrations, especially in the form of microdeletions or microduplications, may affect <italic toggle="yes">WT1</italic> gene expression. <italic toggle="yes">WT1</italic> gene variants and their expression may affect AML prognosis and outcome [<xref rid="B9-jcm-11-01873" ref-type="bibr">9</xref>]. However, the results remain controversial.</p><p>Abnormal divisions of leukemic cells are often the consequence of gene mutations whose products affect the signaling pathways associated with cell proliferation. The prognosis for AML patients is affected not only by <italic toggle="yes">WT1</italic> gene mutation or abnormal expression but also by mutations of the <italic toggle="yes">FLT3</italic>, <italic toggle="yes">NPM1</italic>, and <italic toggle="yes">CEBPA</italic> genes which were also evaluated [<xref rid="B15-jcm-11-01873" ref-type="bibr">15</xref>,<xref rid="B16-jcm-11-01873" ref-type="bibr">16</xref>].</p><p>Most chromosomal aberrations implicate the appearance of certain gene rearrangements, which affect not only the pathogenesis of the disease but also the prognosis and response to the treatment. Clonal chromosomal abnormalities are identified in approximately 55% of adult AML patients and are recognized as independent prognostic factors [<xref rid="B17-jcm-11-01873" ref-type="bibr">17</xref>]. Approximately 15% of patients with clonal changes have complex karyotype, i.e., three or more chromosomal alterations [<xref rid="B18-jcm-11-01873" ref-type="bibr">18</xref>]. Patients with t(8;21), inv(16)/t(16;16), or t(15;17) have a favorable prognosis. The prognosis is poor for AML patients with complex karyotype or with the aberrations including inv(3)/t(3;3), t(6;9), monosomy 5 or del(5q), and monosomy 7 or del(7q) [<xref rid="B19-jcm-11-01873" ref-type="bibr">19</xref>]. The cases of cytogenetically normal AML (CN-AML) are quite heterogeneous and, depending on cryptic molecular changes, are currently classified in the group of intermediate prognoses [<xref rid="B20-jcm-11-01873" ref-type="bibr">20</xref>].</p><p>The aim of our study was the complex assessment of the <italic toggle="yes">WT1</italic> rs16754 variant and <italic toggle="yes">WT1</italic> mutations and expression in relation to chromosomal changes and molecular markers such as mutations in <italic toggle="yes">FLT3</italic>, <italic toggle="yes">NPM1</italic>, and <italic toggle="yes">CEBPA</italic> genes. Taking into account some of the controversies among current reports and conflicting results, we decided to analyze <italic toggle="yes">WT1</italic> variants in the form of mutations and single nucleotide polymorphism, as well as <italic toggle="yes">WT1</italic> gene expression in AML. Such multidimensional analysis has not yet been carried out among AML patients in the Polish population. </p></sec><sec id="sec2-jcm-11-01873"><title>2. Materials and Methods</title><p>The study group consisted of 90 newly-diagnosed AML patients (42 women and 48 men) aged between 18 and 85 years, hospitalized at the Department of Hematooncology and Bone Marrow Transplantation, at the Medical University of Lublin between the years of 2008&#x02013;2020 (<xref rid="jcm-11-01873-t001" ref-type="table">Table 1</xref>). Control samples were of peripheral blood taken from 100 healthy blood donors at the Regional Blood Center of Kielce, Poland.</p><p>The preliminary diagnosis of AML was based on standard FAB (French-American-British) criteria [<xref rid="B11-jcm-11-01873" ref-type="bibr">11</xref>]. On the basis of genetic changes detected at diagnosis, patients were stratified into one of four risk categories: favorable, intermediate-I, intermediate-II, and adverse, according to European Leukemia Net criteria [<xref rid="B20-jcm-11-01873" ref-type="bibr">20</xref>]. The mean time of follow-up was 27 months.</p><p>With informed consent in accordance with the Declaration of Helsinki of 1975, revised in 2008, and after approval from the Medical University Ethics Committee (app. no.: KE-254/24/2011 and KE-0254/229/2013), the bone marrow aspirates were collected to heparin and EDTA collection tubes (Sarstedt, N&#x000fc;mbrecht, Germany), to be used for cell culture and for DNA, RNA isolation, respectively. </p><p>The treatment of patients generally depended on their age, performance status, and medical history. Patients aged 60 years or lower received induction regimen DAC (daunorubicin 60 mg/m<sup>2</sup> on days 1 through 3, continuous infusion of cytarabine 200 mg/m<sup>2</sup> on days 1 through 7, and cladribine 5 mg/m<sup>2</sup> on days 1 through 5). Consolidation treatment consisted of one course of cytarabine 1.5 g/m<sup>2</sup> on days 1 through 3 with mitoxantrone 10 mg/m<sup>2</sup> on days 3 through 5 and one course of high-dose cytarabine 2 g/m<sup>2</sup> twice daily on days 1, 3, and 5. Then those with favorable karyotype or not eligible for hematopoietic stem cell transplantation (HSCT) were treated for about two years with maintenance therapy based on cytarabine combined with daunorubicin or thioguanine; patients with intermediate or adverse karyotype were referred for allogeneic HSCT (allo-HSCT) or auto-HSCT in cases not eligible for allo-HSCT or lacking suitable donor. Patients aged over 60 years of age in good general condition and without significant comorbidities were treated with reduced induction regimen DA (daunorubicin 45 mg/m<sup>2</sup> days 1 through 2 or 3 and continuous infusion of cytarabine 100 mg/m<sup>2</sup> on days 1 through 5 or 7); consolidation and maintenance chemotherapy in this group was reduced as compared with younger patients. Finally, patients over 75 years or younger with significant comorbidities or in poor performance status received low-dose cytarabine (20 mg twice daily for 10 days) repeated every 4 weeks until disease progression. Another treatment option in this group of patients is an azacytidine-a hypomethylating agent used at a dose of 75 mg/m<sup>2</sup> once a day for 7 days during a 28-day cycle. This treatment is continued until unacceptable toxicity or disease progression. Refractory and relapsed patients were treated with different regimens such as ICE (idarubicin, cytarabine, etoposide), CLAG (cladribine, cytarabine, G-CSF), or MEC (mitoxantrone, etoposide, cytarabine). Patients with promyelocytic leukemia received therapy based on idarubicin and ATRA (all-trans-retinoic acid).</p><sec id="sec2dot1-jcm-11-01873"><title>2.1. Classical Cytogenetics and Fluorescence In Situ Hybridization (FISH)</title><p>Unstimulated cultures of both leukemic (from the first portion of the bone marrow aspirates) and normal (peripheral blood of healthy donors) cells were performed in 15 mL of growth medium (RPMI 1640 medium supplemented with 15% FCS, 100 U/mL penicillin, and 50 &#x003bc;g/mL streptomycin 50 &#x003bc;g/mL, Biomed). The cells were cultured for 24&#x02013;72 h, and then cultures were terminated conventionally. Metaphase spreads were stained using banding techniques (GTG and RHG bands). Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2020 [<xref rid="B4-jcm-11-01873" ref-type="bibr">4</xref>].</p><p>FISH was initially performed on uncultured cells from the diagnostic bone marrow specimens using following probes: 13q14.3, D13S319 and D13S25, 5q (5p15.31 and <italic toggle="yes">EGR1</italic>), 7q (7q22.1 and 7q31), 20q (20q12 and 20q13.2), <italic toggle="yes">EVI1</italic> (3q26) breakapart, <italic toggle="yes">MLL</italic> (11q23), <italic toggle="yes">IGH/CCND1</italic> (14q32.3/11q13), <italic toggle="yes">EGFR</italic> (7p11.2), <italic toggle="yes">EWSR1/ERG</italic> (21q22; 22q12)<italic toggle="yes">, MDM2</italic> (12q14.3-q15), <italic toggle="yes">IGH/BCL2</italic> (14q32.3; 18q21) (all from Cytocell), dual-fusion probe the <italic toggle="yes">PML</italic> (15q22) and <italic toggle="yes">RARA</italic> (17q21.1) <italic toggle="yes">loci</italic>, 21q (D21S259, D21S341, D21S342, 21q22.13&#x02013;q22.2), 17q23/17p12, TP53/CEP17, D5S23/D5S721 (5p15.2), EGR1 (5q31), CEP7/D7S486 (7q31), D8Z2 (CEP8), <italic toggle="yes">MYC</italic> (8q24.12&#x02013;24.13), <italic toggle="yes">CDKN2A</italic> (9p21), <italic toggle="yes">MYB</italic> (6q23), CEP9 (9p11&#x02013;q11), <italic toggle="yes">ETV6</italic> (12p13), CEP15 (D15Z4), CEP17 (D17Z1), D20S108 (20q12), D13S319 (13q14.3)/13q34, <italic toggle="yes">RUNX1</italic> (21q22), dual-fusion probe the <italic toggle="yes">BCR</italic> (22q11.2) and <italic toggle="yes">ABL</italic> (9q34) <italic toggle="yes">loci</italic>, <italic toggle="yes">AML1/ETO</italic> (21q22/8q22) (all from VYSIS, Abbott Laboratories), 1q21/SRD (1p36), hTERT 5p15/5q31, <italic toggle="yes">DEK/NUP214</italic> (6p22; 9q34), <italic toggle="yes">FGFR1</italic>(8p12), <italic toggle="yes">MAF/IGH</italic> (16q23; 14q32), <italic toggle="yes">BCL1/IGH</italic> (11q13; 14q32), 22q11/22q13 (all from KREATECH Diagnostics). FISH was performed according to the manufacturer&#x02019;s instructions. A total of 200 interphase cells per each sample were examined. The cutoff level for each individual probe was determined based on negative sample analysis and calculated as the mean &#x000b1; 3SD.</p></sec><sec id="sec2dot2-jcm-11-01873"><title>2.2. DNA Isolation</title><p>DNA isolation from bone marrow aspirates (AML samples) and peripheral blood (control samples) was performed using a commercial kit (Qiagen, Hilden, Germany), according to the procedure provided by the manufacturer. The concentration and quality of isolated DNA were checked spectrophotometrically with NanoDrop 2000 (Thermo Scientific, Waltham, MA, USA). DNA was stored at &#x02212;20 &#x000b0;C. DNA from bone marrow aspirates was used to analyze chromosomal aberrations (with array CGH method) and <italic toggle="yes">WT1</italic> genotyping (with DNA sequencing method). DNA isolated from peripheral blood was used to analyze the <italic toggle="yes">WT1</italic> rs16754 variant.</p></sec><sec id="sec2dot3-jcm-11-01873"><title>2.3. Array Comparative Genomic Hybridization (aCGH)</title><p>Each step of the aCGH method was performed according to the manufacturer&#x02019;s (PerkinElmer, Waltham, MA, USA) instructions. The microarrays (Constitutional Chip 4.0) contained human DNA clones (about 100&#x02013;300 kb long) derived from artificial bacterial chromosomes (BAC probes), which covered the entire human genome. The average resolution of the probes was less than 650 kb.</p><p>The process of array hybridization was carried out in HS 400 Pro hybridization station (Tecan, Mennedorf, Switzerland). Array scanning was performed in a ScanArrayGx scanner (PerkinElmer). The OneClick software (PerkinElmer) was used to analyze the results obtained with the aCGH technique. The results were described according to ISCN 2020 [<xref rid="B4-jcm-11-01873" ref-type="bibr">4</xref>]. </p></sec><sec id="sec2dot4-jcm-11-01873"><title>2.4. WT1 Genotyping&#x02014;Analysis of WT1 Mutations and rs16754 Variant</title><p>The determination of all possible mutations in exons 7 and 9 and rs16754 variant (in exon 7) of the <italic toggle="yes">WT1</italic> gene was performed using direct sequencing. Primer sequences and the procedure of sequencing were performed according to Summers et al., 2007 [<xref rid="B21-jcm-11-01873" ref-type="bibr">21</xref>]. A total of 25 &#x003bc;L reaction mixture consisted of 100 ng genomic DNA, 10 &#x000b5;M of each primer, 0.25 mM dNTPs mixture, and 0.31 U of HD polymerase (Clontech) with 1 &#x000d7; PCR reaction buffer (Clontech). PCR reactions with modified thermal conditions were the same for exon 7 and 9 analysis: initial denaturation (98 &#x000b0;C-3 min), 35 cycles (98 &#x000b0;C-20 s, 60 &#x000b0;C-10 s, 72 &#x000b0;C-15 s), final elongation (72 &#x000b0;C-5 min). The PCR reactions were performed in Applied Biosystems 9700 Thermal Cycler. Sequencing PCR was performed using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Waltham, MA, USA) in a thermal cycler (as previously). The sequencing PCR product was purified using an exterminator kit (A&#x00026;A Biotechnology, Gdynia, Poland). The sequencing run module was StdSeq50_POP7 in genetic analyzer 3130 (Applied Biosystems). The results were analyzed by use of Applied Biosystems software.</p></sec><sec id="sec2dot5-jcm-11-01873"><title>2.5. RNA Isolation and WT1 Expression </title><p>RNA isolation was carried out according to the procedure developed by Chomczynski and Sacchi [<xref rid="B22-jcm-11-01873" ref-type="bibr">22</xref>]. The concentration of isolated RNA was checked spectrophotometrically using a NanoDrop device (Thermo Scientific). The quality of this nucleic acid was checked during electrophoresis in 2% agarose gel. RNA was stored at &#x02212;80 &#x000b0;C. </p><p>After RNA isolation, the reverse transcription reaction was performed (A&#x00026;A Biotechnology set). The real-time PCR reaction (Applied Biosystems 7500 Fast) was carried out on the cDNA (100 ng) template. The analysis of <italic toggle="yes">WT1</italic> gene expression was performed using a <italic toggle="yes">WT1</italic> ProfileQuant (Ipsogen, Marseille, France) kit. In real-time PCR, we used primers and probes with the sequences described by Cillioni et al. [<xref rid="B23-jcm-11-01873" ref-type="bibr">23</xref>]. The <italic toggle="yes">ABL</italic> gene was the reference gene. The sequences of the primers and probes for <italic toggle="yes">ABL</italic> were used according to the protocol described by Beillard et al. [<xref rid="B24-jcm-11-01873" ref-type="bibr">24</xref>]. In accordance with the LeukemiaNet guidelines, the detection of more than 250 copies of <italic toggle="yes">WT1</italic>/10,000 copies of the control <italic toggle="yes">ABL</italic> gene was defined as <italic toggle="yes">WT1</italic> overexpression [<xref rid="B23-jcm-11-01873" ref-type="bibr">23</xref>,<xref rid="B25-jcm-11-01873" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot6-jcm-11-01873"><title>2.6. Analysis for Other Gene Mutations</title><p><italic toggle="yes">FLT3</italic> and <italic toggle="yes">NPM1</italic> gene mutations were analyzed as previously described [<xref rid="B26-jcm-11-01873" ref-type="bibr">26</xref>]. The detection of <italic toggle="yes">CEBPA</italic> gene mutation was according to Benthaus et al. 2008 [<xref rid="B27-jcm-11-01873" ref-type="bibr">27</xref>]. </p></sec><sec id="sec2dot7-jcm-11-01873"><title>2.7. Statistical Analysis </title><p>The efficacy of induction therapy was assessed using response criteria proposed by European Leukemia Net [<xref rid="B20-jcm-11-01873" ref-type="bibr">20</xref>]. Overall survival (OS) was defined as the time from diagnosis to death from any cause. Relapse-free survival (RFS) was defined as time calculated from the achievement of remission until the date of relapse or death from any cause. The probabilities of OS and RFS rates were estimated using the Kaplan&#x02013;Meier method. Genetic risk groups were compared with respect to these parameters using the log-rank test. In the case of <italic toggle="yes">WT1</italic> rs16754 variant, deviations in genotype frequencies in controls (healthy blood donors) and cases (AML patients) from Hardy&#x02013;Weinberg equilibrium (HWE) were assessed by Chi-squared test with Yates&#x02019;s correction for the groups with less than five patients [<xref rid="B28-jcm-11-01873" ref-type="bibr">28</xref>]. For 95% confidence interval (CI), we assumed <italic toggle="yes">p</italic> = 0.05 and &#x003c7;<sup>2</sup> = 3.84; therefore, if the &#x003c7;<sup>2</sup> &#x02264; 3.84 and the corresponding <italic toggle="yes">p</italic> &#x02265; 0.05, then the population is in HWE, as described previously by Zmorzynski et al., 2019 [<xref rid="B29-jcm-11-01873" ref-type="bibr">29</xref>]. Differences with a <italic toggle="yes">p</italic> value less than 0.05 were considered statistically significant. Statistica software version 12.0 (Statsoft, Tulsa, AK, USA) was used for statistical analysis.</p></sec></sec><sec sec-type="results" id="sec3-jcm-11-01873"><title>3. Results</title><p>The presented study included 90 AML patients, 42 males and 48 females, with a median age of 62.63 years. Cytogenetic and molecular analyzes were successful in all the individuals investigated within the study.</p><sec id="sec3dot1-jcm-11-01873"><title>3.1. WT1 rs16754 Variant</title><p>The HWE test showed that the genotypic frequencies of the <italic toggle="yes">WT1</italic> rs16754 variant were not in HWE for AML patients (<xref rid="jcm-11-01873-t002" ref-type="table">Table 2</xref>). The differences in the genotypic and allelic frequencies of <italic toggle="yes">WT1</italic> between the study and control groups were statistically insignificant (<xref rid="jcm-11-01873-t003" ref-type="table">Table 3</xref>).</p><p>The studied <italic toggle="yes">WT1</italic> variant did not influence the risk of AML. Genotypes AA predominated in the intermediate risk group (33/74). Genotypes AA and GA predominated in the adverse risk group (28/74 and 12/13, respectively). All cases with poor risks had homozygous GG (3/3). The presence of GA and GG genotypes did not affect the risk of <italic toggle="yes">WT1</italic> mutations occurrence (<italic toggle="yes">p</italic> = 0.68). We observed higher expression of <italic toggle="yes">WT1</italic> gene in patients with AA genotype in comparison with those with GA or GG genotypes&#x02014;10,556.7 vs. 25,836.5 NCN copies (<italic toggle="yes">p</italic> = 0.01), respectively. The AA genotypes were associated with lower PLT numbers in comparison with GA + GG genotypes&#x02014;78.37 vs. 137.18 (G/L), <italic toggle="yes">p</italic> = 0.02 (<xref rid="jcm-11-01873-t004" ref-type="table">Table 4</xref>). Survival curves were defined by the Kaplan&#x02013;Meier method and compared using the log-rank test. Among surviving patients, there were no statistically significant differences in OS and RFS between patients with AA genotype and those with GA or GG genotypes&#x02014;<italic toggle="yes">p</italic> = 0.302 and <italic toggle="yes">p</italic> = 0.365, respectively (<xref rid="jcm-11-01873-f001" ref-type="fig">Figure 1</xref> and <xref rid="jcm-11-01873-f002" ref-type="fig">Figure 2</xref>). </p></sec><sec id="sec3dot2-jcm-11-01873"><title>3.2. WT1 Mutations</title><p><italic toggle="yes">WT1</italic> mutations were found in 26/90 patients (28.9%). A total of 13 patients had <italic toggle="yes">WT1</italic> mutations affecting exon 7 (14.4%), whereas 12 patients (13.3%) had <italic toggle="yes">WT1</italic> mutations in exon 9. Only one patient had <italic toggle="yes">WT1</italic> mutations in both exon 7 and 9 (1.1%). The total number of <italic toggle="yes">WT1</italic> mutations was 24. We found the following mutations:<list list-type="simple"><list-item><label>-</label><p>In exon 7: c.1375G&#x0003e;A (p.A399V), c.1334C&#x0003e;A (p.R385R), c.1382A&#x0003e;T (p.P401P), c.1389delA (p.N404H); c.1320G&#x0003e;A (p.P381S), c.1314C&#x0003e;T (p.V379I), c.1324indelGTACAAGAG/GTACAAGAGGGTACAAGAG (frameshift variant);</p></list-item><list-item><label>-</label><p>In exon 9: c.1590delC (p.L491X), c.1567G&#x0003e;A (p.R463P), c.1557T&#x0003e;A/C (p.T460S/A).</p></list-item></list></p><p>The most common mutations were substitutions (18/24, 75%). In contrast, deletions were found in 5 cases (5/24, 20.8%). One indel mutation was found (1/24, 4.1%). </p><p><italic toggle="yes">WT1</italic> mutations were present more frequently in AML patients with age under 65 years (<italic toggle="yes">p</italic> &#x0003c; 0.0001) (<xref rid="jcm-11-01873-t004" ref-type="table">Table 4</xref>). The presence of <italic toggle="yes">NPM1</italic> or <italic toggle="yes">CEBPA</italic> mutations decreased the risk of mutations occurrence in <italic toggle="yes">WT1</italic> gene-OR = 0.11, 95% CI 0.02&#x02013;0.46, <italic toggle="yes">p</italic> = 0.002 or OR = 0.05, 95% CI 0.006&#x02013;0.46, <italic toggle="yes">p</italic> = 0.002, respectively (<xref rid="jcm-11-01873-t004" ref-type="table">Table 4</xref>). <italic toggle="yes">WT1</italic> mutation, as well as <italic toggle="yes">WT1</italic> rs16754 genotypes, did not affect the OS of AML patients (<xref rid="jcm-11-01873-f001" ref-type="fig">Figure 1</xref>). We observed an association of <italic toggle="yes">WT1</italic> mutations with RFS (<xref rid="jcm-11-01873-f002" ref-type="fig">Figure 2</xref>a). A univariate Cox analysis revealed that patients above 65 years of age had a 2.5-fold risk of death, <italic toggle="yes">p</italic> = &#x0003c;0.01 HR = 2.52 (<xref rid="jcm-11-01873-t005" ref-type="table">Table 5</xref>).</p></sec><sec id="sec3dot3-jcm-11-01873"><title>3.3. WT1 Expression</title><p>The number of <italic toggle="yes">WT1</italic> gene copies (normalized copy number, NCN) was calculated into 10,000 <italic toggle="yes">ABL</italic> gene copies. A value of &#x0003e;250 <italic toggle="yes">WT1</italic> copies per 10,000 <italic toggle="yes">ABL</italic> copies was seen as a manifestation of overexpression of this <italic toggle="yes">WT1</italic> gene. The <italic toggle="yes">WT1</italic> overexpression was observed in all AML patients at the time of diagnosis. The mean of <italic toggle="yes">WT1</italic> expression was 13,273.12 (range from 1342.9 to 172,093). In patients with normal karyotype and with chromosomal aberrations, we observed mean <italic toggle="yes">WT1</italic> expression 12,747.44 (range 1342.9&#x02013;172,093) and 13,798.79 (range 1458&#x02013;105,842.5). The difference in <italic toggle="yes">WT1</italic> expression between patients with normal and abnormal karyotypes was statistically insignificant (<xref rid="jcm-11-01873-t004" ref-type="table">Table 4</xref>). We observed significantly higher <italic toggle="yes">WT1</italic> expression in AML CD34 positive patients in comparison with AML CD34 negative individuals&#x02014;20,985 (NCN) vs. 8304 (NCN), <italic toggle="yes">p</italic> = 0.039.</p></sec><sec id="sec3dot4-jcm-11-01873"><title>3.4. FLT3, NPM1, and CEBPA Mutations</title><p>Internal tandem duplication of <italic toggle="yes">FLT3</italic> gene (<italic toggle="yes">FLT3</italic>-ITD) was observed in eight patients (8.8%). In all cases, <italic toggle="yes">FLT3</italic>-ITD change involved only one allele. In six patients with <italic toggle="yes">FLT3</italic>-ITD, complete remission could not be achieved. We did not observe a statistically significant difference between <italic toggle="yes">WT1</italic> gene expression in patients with <italic toggle="yes">FLT3</italic>-ITD and patients with <italic toggle="yes">FLT3</italic> wild type-13,628 vs. 13,238, <italic toggle="yes">p</italic> = 0.98. In patients with <italic toggle="yes">FLT3</italic> mutation, hyperleukocytosis was observed in comparison with those with <italic toggle="yes">FLT3</italic> wild type&#x02014;49.5 vs. 152 G/L (<italic toggle="yes">p</italic> = 0.002), respectively. In patients who reached CR, a lower WBC number was observed&#x02014;22.9 vs. 59 (G/L), <italic toggle="yes">p</italic> = 0.012. <italic toggle="yes">FLT3</italic> mutation did not impact CR in AML patients (<italic toggle="yes">p</italic> = 0.81).</p><p><italic toggle="yes">NPM1</italic> mutational analysis revealed a type A mutation in exon 12 (956dupTCTG). This type of mutation was observed in 11 patients. Both <italic toggle="yes">FLT3</italic>-ITD and <italic toggle="yes">NPM1</italic> mutations did not coexist together. The mean number of <italic toggle="yes">WT1</italic> copies in patients with <italic toggle="yes">NPM1</italic> mutation was lower than the median value (7663.26 NCN). However, this difference in mean <italic toggle="yes">WT1</italic> NCN copies between AML patients with or without <italic toggle="yes">NPM1</italic> mutation was statistically insignificant (<italic toggle="yes">p</italic> = 0.71). Similar results were observed in the case of patients with or without <italic toggle="yes">CEBPA</italic> mutation&#x02014;7356 vs. 13,772 <italic toggle="yes">WT1</italic> NCN (<italic toggle="yes">p</italic> = 0.43), respectively. <italic toggle="yes">CEBPA</italic> mutation coexisted with <italic toggle="yes">NPM1</italic> mutation in three cases. In one AML patient, the presence of both&#x02013;<italic toggle="yes">CEBPA</italic> mutation and <italic toggle="yes">FLT3</italic>-ITD was observed. A univariate Cox analysis identified <italic toggle="yes">NPM1</italic> mutation impacting RFS of AML patients (<italic toggle="yes">p</italic> = 0.04, HR = 3.46) (<xref rid="jcm-11-01873-t005" ref-type="table">Table 5</xref>). In multivariate Cox analysis, we did not observe any impact of <italic toggle="yes">WT1</italic> mutation, <italic toggle="yes">WT1</italic> overexpression, or molecular changes in <italic toggle="yes">FLT3</italic>, <italic toggle="yes">NPM1</italic>, and <italic toggle="yes">CEBPA</italic> genes on OS and RFS in AML patients. </p></sec><sec id="sec3dot5-jcm-11-01873"><title>3.5. Cytogenetic Aberrations</title><p>In our study, by use of conventional cytogenetics and aCGH, genomic imbalances were detected in 45 cases (50%). Owing to the aCGH technique, we detected an abnormal number of chromosomes that included gains and losses, as well as small structural changes in the form of duplications and deletions. </p><p>The aberrations detected with classical cytogenetic techniques included whole chromosomes. These changes were mostly related to the following chromosomes: &#x02212;17 (11%); &#x02212;18 (9%); &#x02212;5 (8%), +8, &#x02212;15, &#x02212;16, &#x02212;21 (7%); &#x02212;3, +6, &#x02212;7, &#x02212;12, &#x02212;14, &#x02212;20, &#x02212;22 (5%). Interstitial and terminal deletions were also detected (del(3q), del(5q), del(7q), del(11q), del(13q), del(17p)), translocations (t(3;15), t(5;7), t(8;16), t(8;21), t(9;22), t(10;12), t(11;11) and t(15;17)), inversions (inv(16)), isochromosomes (i(17q)) and the presence of marker chromosomes.</p><p>The chromosomal aberrations revealed by aCGH included small DNA fragments and were predominantly related to the following regions: <list list-type="simple"><list-item><label>-</label><p>losses of (5)(q23q32)&#x02014;20%;</p></list-item><list-item><label>-</label><p>losses of (7)(p12.3q36.3)&#x02014;13%;</p></list-item><list-item><label>-</label><p>gains of (8)(q12.1q24.3)&#x02014;10%;</p></list-item><list-item><label>-</label><p>gains of (11)(q12.2q14.1)&#x02014;12.2%;</p></list-item><list-item><label>-</label><p>losses of (11)(q22q23.3)&#x02014;14.4%;</p></list-item><list-item><label>-</label><p>losses of (17)(p13.3p13.1)&#x02014;16.7%;</p></list-item><list-item><label>-</label><p>losses of (18)(p11.32q23)&#x02014;11%;</p></list-item><list-item><label>-</label><p>gains of (22)(q12.3q13.2)&#x02014;5.5%.</p></list-item></list></p><p>By using the aCGH technique, we have confirmed the occurrence of most changes detected by classical cytogenetic methods. In our study, we observed amplification of regions&#x02014;3q26 (<italic toggle="yes">EVI1</italic> gene <italic toggle="yes">locus</italic>), 8q24 (<italic toggle="yes">C-MYC</italic> gene <italic toggle="yes">locus</italic>), and 11q23 (<italic toggle="yes">MLL</italic> gene <italic toggle="yes">locus</italic>). </p><p>No chromosome X and Y aberrations were found using the microarray CGH method; however, such aberrations were seen in classical cytogenetics tests. In the case of deletions and additions, no statistically significant differences were found between the results obtained by classical cytogenetics (GTG and RHG) and aCGH.</p><p>The combination of conventional cytogenetics, FISH, and aCGH enabled us to find favorable karyotype in 13 patients (14.4%), intermediate karyotype in 34 patients (37.7%), and adverse karyotype in 43 patients (47.7%). The median OS was not reached in favorable-risk (26.6 months) and in adverse-risk group (12.8 months). It was reached in intermediate-risk group 39.7 months (<italic toggle="yes">p</italic> = 0.123 favorable vs. intermediate; <italic toggle="yes">p</italic> = 0.001 favorable vs. adverse; <italic toggle="yes">p</italic> = 0.001 intermediate vs. adverse). The median RFS (6.39 months) was not reached in adverse-risk group (1.8 month) in comparison with favorable-risk (10.5 months) and intermediate-risk (8.6 months) groups (<italic toggle="yes">p</italic> = 0.125 favorable vs. intermediate; <italic toggle="yes">p</italic> = 0.002 favorable vs. adverse; <italic toggle="yes">p</italic> = 0.017 intermediate vs. adverse). </p></sec></sec><sec sec-type="discussion" id="sec4-jcm-11-01873"><title>4. Discussion</title><p>In our study, we analyzed the <italic toggle="yes">WT1</italic> rs16754 variant, <italic toggle="yes">WT1</italic> mutations, and <italic toggle="yes">WT1</italic> gene expression taking into account chromosomal changes and molecular markers such as mutations in <italic toggle="yes">FLT3</italic>, <italic toggle="yes">NPM1</italic>, and <italic toggle="yes">CEBPA</italic> genes. To our knowledge, our investigation is the first multidimensional study including analysis of cryptic chromosomal and molecular changes in Polish AML patients.</p><sec id="sec4dot1-jcm-11-01873"><title>4.1. WT1 rs16754 Variant</title><p>In our study, we found that genotypic frequencies of the <italic toggle="yes">WT1</italic> gene were not in HWE. This suggests an association of <italic toggle="yes">WT1</italic> rs16754 genotypes with the risk of disease development. However, in our study, we did not find the association of analyzed genotypes with AML risk. We cannot exclude, however, that the obtained result was due to sampling error. Moreover, analyzed genotypes did not affect OS or RFS of AML patients. It is consistent with results obtained by Kim et al. in Korean patients with AML [<xref rid="B30-jcm-11-01873" ref-type="bibr">30</xref>]. In contrast, Long et al. in their meta-analysis observed that the <italic toggle="yes">WT1</italic> rs16754 variant was associated with better survival of AML patients [<xref rid="B9-jcm-11-01873" ref-type="bibr">9</xref>]. They concluded that the <italic toggle="yes">WT1</italic> rs16754 variant was an independent favorable-risk marker [<xref rid="B9-jcm-11-01873" ref-type="bibr">9</xref>]. Zhang et al. found that GG genotypes were associated with significantly higher <italic toggle="yes">WT1</italic> expression at mRNA level in comparison with GA and AA genotypes [<xref rid="B31-jcm-11-01873" ref-type="bibr">31</xref>]. In our study, we observed similar results. The expression of the <italic toggle="yes">WT1</italic> gene was statistically higher in AML patients with AA genotype. </p></sec><sec id="sec4dot2-jcm-11-01873"><title>4.2. WT1 Mutations</title><p>We observed a higher frequency of <italic toggle="yes">WT1</italic> mutations in AML patients under 65 years of age. This is in concordance with results obtained by Krauth et al. [<xref rid="B32-jcm-11-01873" ref-type="bibr">32</xref>]. In their study of 3157 AML patients, they found that <italic toggle="yes">WT1</italic> mutations were more frequent in younger AML patients and were associated with adverse effects in cytogenetically normal AML patients [<xref rid="B32-jcm-11-01873" ref-type="bibr">32</xref>]. In concordance with other studies, we did not find a significant relationship between <italic toggle="yes">WT1</italic> mutations and clinical characteristics, including gender, WBC and PLT count, and Hb concentration [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>,<xref rid="B33-jcm-11-01873" ref-type="bibr">33</xref>]. We did not find an association of <italic toggle="yes">WT1</italic> mutations with normal karyotype. However, we observed a higher frequency of <italic toggle="yes">WT1</italic> mutations in AML patients with <italic toggle="yes">NPM1</italic> or <italic toggle="yes">CEBPA</italic> genes mutations. More frequent <italic toggle="yes">WT1</italic> mutations were observed by Krauth and coworkers in <italic toggle="yes">CEBPA</italic> mutated AML [<xref rid="B32-jcm-11-01873" ref-type="bibr">32</xref>]. In contrast, Hou et al. and Rostami et al. did not observe a relationship between <italic toggle="yes">WT1</italic> mutations and the presence of mutations in genes-<italic toggle="yes">FLT3</italic>, <italic toggle="yes">NPM1</italic>, and <italic toggle="yes">CEBPA</italic> [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>,<xref rid="B34-jcm-11-01873" ref-type="bibr">34</xref>]. In other research, Toogeh and coworkers showed no correlation of <italic toggle="yes">WT1</italic> mutations with <italic toggle="yes">FLT3</italic>-ITD [<xref rid="B35-jcm-11-01873" ref-type="bibr">35</xref>]. In our study, we did not observe an association of <italic toggle="yes">WT1</italic> mutations with <italic toggle="yes">FLT3</italic>-ITD. To assess the prognostic impact of <italic toggle="yes">WT1</italic> mutations, we analyzed them taking into account OS and RFS. We found longer RFS in patients with <italic toggle="yes">WT1</italic> mutation. However, this result is not consistent with previous reports [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>,<xref rid="B33-jcm-11-01873" ref-type="bibr">33</xref>,<xref rid="B36-jcm-11-01873" ref-type="bibr">36</xref>,<xref rid="B37-jcm-11-01873" ref-type="bibr">37</xref>]. This may be due to the fact that previous reports were conducted in other populations or as a result of sampling error. </p></sec><sec id="sec4dot3-jcm-11-01873"><title>4.3. WT1 Expression</title><p>The <italic toggle="yes">WT1</italic> gene shows high expression in AML patients, and its expression at diagnosis may be an adverse predictor of disease outcome [<xref rid="B38-jcm-11-01873" ref-type="bibr">38</xref>]. It has been confirmed that increased expression of the <italic toggle="yes">WT1</italic> gene accelerated disease progression [<xref rid="B38-jcm-11-01873" ref-type="bibr">38</xref>]. In our study, we observed <italic toggle="yes">WT1</italic> overexpression in 97.7% of newly diagnosed AML patients, which is in agreement with previous studies [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>,<xref rid="B10-jcm-11-01873" ref-type="bibr">10</xref>,<xref rid="B16-jcm-11-01873" ref-type="bibr">16</xref>]. In the presented material, all patients qualified for the study had completed chemotherapy. We observed significantly higher <italic toggle="yes">WT1</italic> expression in AML CD34 positive patients in comparison with AML CD34 negative individuals. Yoon et al. carried out testing of 104 diagnosed AML patients with normal karyotype and showed that increased <italic toggle="yes">WT1</italic> expression in bone marrow was significantly increased in AML patients [<xref rid="B39-jcm-11-01873" ref-type="bibr">39</xref>]. We did not find a statistically significant difference in <italic toggle="yes">WT1</italic> expression between patients with normal and abnormal karyotypes. Moreover, we did not observe an association between <italic toggle="yes">WT1</italic> expression and OS or RFS. Results of our research confirm the data obtained by other authors [<xref rid="B3-jcm-11-01873" ref-type="bibr">3</xref>,<xref rid="B40-jcm-11-01873" ref-type="bibr">40</xref>].</p></sec><sec id="sec4dot4-jcm-11-01873"><title>4.4. Cytogenetic Analysis</title><p>We observed the occurrence of chromosome abnormalities, which were identified by conventional karyotype testing, aCGH, and were confirmed by FISH testing. Without conventional cytogenetics and FISH, we would not be able to detect and resolve balanced aberrations, such as translocations. Similar results were found in numerous studies [<xref rid="B19-jcm-11-01873" ref-type="bibr">19</xref>,<xref rid="B20-jcm-11-01873" ref-type="bibr">20</xref>]. Our data also support the importance of cytogenetic analysis as a component of the routine diagnostic workup of AML. </p><p>The difference in <italic toggle="yes">WT1</italic> expression between patients with normal and abnormal karyotypes was statistically insignificant. Moreover, we did not observe an association between chromosomal aberrations and the presence of <italic toggle="yes">WT1</italic> mutations.</p><p>The median OS was not reached in the favorable-risk group, as well as in the adverse-risk group. In the case of RFS, its median value was not reached in the adverse-risk group only. </p><p>The aberration frequently observed using aCGH was the loss of a long arm fragment of chromosome 5 (including <italic toggle="yes">NPM1</italic> gene <italic toggle="yes">locus</italic>), which is in agreement with other studies [<xref rid="B41-jcm-11-01873" ref-type="bibr">41</xref>,<xref rid="B42-jcm-11-01873" ref-type="bibr">42</xref>]. Costa et al. and Rucker et al. detected losses of small regions in 5q [<xref rid="B43-jcm-11-01873" ref-type="bibr">43</xref>,<xref rid="B44-jcm-11-01873" ref-type="bibr">44</xref>]. Mehrotra et al. analyzed 48 AML patients and observed deletions in the 5q33.3 region [<xref rid="B45-jcm-11-01873" ref-type="bibr">45</xref>]. Loss of this region was associated with the achievement of CR [<xref rid="B45-jcm-11-01873" ref-type="bibr">45</xref>]. Veigaard et al. drew attention to the 5q23.1&#x02013;q33.3 region, where they found deletions most frequently [<xref rid="B46-jcm-11-01873" ref-type="bibr">46</xref>]. In addition, Schoch et al., in testing AML patients with complex karyotype, found deletions of the 5q14&#x02013;q35 region, as we did in our study [<xref rid="B47-jcm-11-01873" ref-type="bibr">47</xref>]. Itzhar et al. specified 5q31.3&#x02013;q32 regions which were associated with AML development [<xref rid="B48-jcm-11-01873" ref-type="bibr">48</xref>]. The deletion of the 5q31 region was associated with the aggressive course of AML, the occurrence of additional chromosomal aberrations, and an unfavorable prognosis [<xref rid="B46-jcm-11-01873" ref-type="bibr">46</xref>]. We did not detect microdeletions or microduplications of <italic toggle="yes">loci,</italic> including <italic toggle="yes">WT1</italic>, <italic toggle="yes">FLT3</italic>, and <italic toggle="yes">CEBPA</italic> genes.</p></sec><sec id="sec4dot5-jcm-11-01873"><title>4.5. Clinical and Molecular Data</title><p><italic toggle="yes">NPM1</italic> mutations in AML patients are associated with the presence of normal karyotype and are rare in patients with genetic aberrations [<xref rid="B49-jcm-11-01873" ref-type="bibr">49</xref>]. We did not notice shorter OS or RFS in patients with <italic toggle="yes">NPM1</italic> mutation. The presence of this mutation is favorable and is associated with higher CR rates [<xref rid="B4-jcm-11-01873" ref-type="bibr">4</xref>]. In CN-AML patients with <italic toggle="yes">NPM1</italic> mutation, longer RFS is observed in comparison with that observed in patients with wild-type <italic toggle="yes">NPM1</italic> [<xref rid="B20-jcm-11-01873" ref-type="bibr">20</xref>]. In our study, we observed <italic toggle="yes">NPM1</italic> gene mutations only in CN-AML. Patients with <italic toggle="yes">NPM1</italic> mutations and lacking <italic toggle="yes">FLT3</italic>-ITD have a better prognosis [<xref rid="B50-jcm-11-01873" ref-type="bibr">50</xref>]. The coexistence of <italic toggle="yes">NPM1</italic> and <italic toggle="yes">FLT3</italic>-ITD mutations is a relatively common phenomenon, observed in about 18% of patients with CN-AML [<xref rid="B51-jcm-11-01873" ref-type="bibr">51</xref>]. In our material, we did not find the coexistence of these mutations. Many studies have confirmed the correlation between <italic toggle="yes">FLT3</italic>-ITD and an increased number of leukocytes [<xref rid="B52-jcm-11-01873" ref-type="bibr">52</xref>]. Our research has also shown that patients with <italic toggle="yes">FLT3</italic>-ITD mutations have increased leukocytosis. The <italic toggle="yes">FLT3</italic>-ITD adversely affects the response to treatment. However, in the presented material, we did not find an association between CR rate and the presence of the <italic toggle="yes">FLT3</italic> mutation.</p></sec><sec id="sec4dot6-jcm-11-01873"><title>4.6. Limitations</title><p>The limitations of our study are associated with the number of AML patients recruited to the study, as well as an automated DNA sequencing method. The sample size was relatively small, in part due to the low incidence of the disease, as well as applied methods such as aCGH. Chromosomal aberrations are factors that need to be taken into account in determining the prognosis of AML patients. Due to their low resolution, the techniques of classical cytogenetics do not detect all alterations; therefore, other methods are used in diagnosing AML, such as PCR and FISH. However, both techniques require prior knowledge of DNA regions where the mutations have occurred. The 90 AML patients sufficed for most analyzes. However, some were not possible as a result of the low frequency of certain molecular changes. In the case of automated sequencing, it would be recommended to use the next-generation sequencing, which has higher resolution and enables analysis of all exons and introns of the <italic toggle="yes">WT1</italic> gene. It is possible that mutations present in other coding regions or in regulatory regions of the <italic toggle="yes">WT1</italic> gene were not detected in our analysis. </p></sec><sec id="sec4dot7-jcm-11-01873"><title>4.7. Conclusions</title><p><italic toggle="yes">WT1</italic> gene expression and its rs16754 variant at diagnosis did not affect outcomes in Polish AML patients. <italic toggle="yes">WT1</italic> mutation may affect RFS in AML. In conclusion, we propose a combination of conventional cytogenetics, FISH, and array CGH as necessary tools to unravel the molecular karyotype of AML.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>Special thanks are due to Paul Dudek for proofreading and editing assistance, as well as substantive verification.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Experiments and molecular analysis of <italic toggle="yes">WT1</italic> variants and expression, S.Z. and S.P.-M.; mutation analysis, S.P.-M.; cytogenetic analysis (including classical cytogenetics, array CGH, and FISH) and results interpretation, D.K., B.G. and B.P.-G.; planning and supervision, A.A.F.; experimental data processing and analysis, S.Z. and W.S.; figure design, S.Z. and W.S.; writing&#x02014;original draft preparation, review and editing, S.Z., D.K. and A.A.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This project was supported by the Medical University of Lublin, Poland (Grants MNmb 232, PBmb240 and DS 225).</p></notes><notes><title>Institutional Review Board Statement</title><p>The study obtained positive opinions (no. KE-254/24/2011 and KE-0254/229/2013) of the Bioethics Committee of Medical University of Lublin, according to the ethical standards established by Helsinki Declaration. All methods were performed in accordance with the relevant guidelines and regulations. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The clinical data used to support the findings of this study are available from the corresponding author upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-jcm-11-01873"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Estey</surname><given-names>E.</given-names></name>
<name><surname>D&#x000f6;hner</surname><given-names>H.</given-names></name>
</person-group><article-title>Acute myeloid leukaemia</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1894</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69780-8</pub-id><pub-id pub-id-type="pmid">17126723</pub-id></element-citation></ref><ref id="B2-jcm-11-01873"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>J.P.</given-names></name>
<name><surname>G&#x000f6;nen</surname><given-names>M.</given-names></name>
<name><surname>Figueroa</surname><given-names>M.E.</given-names></name>
<name><surname>Fernandez</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Racevskis</surname><given-names>J.</given-names></name>
<name><surname>Van Vlierberghe</surname><given-names>P.</given-names></name>
<name><surname>Dolgalev</surname><given-names>I.</given-names></name>
<name><surname>Thomas</surname><given-names>S.</given-names></name>
<name><surname>Aminova</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>366</volume><fpage>1079</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1112304</pub-id><pub-id pub-id-type="pmid">22417203</pub-id></element-citation></ref><ref id="B3-jcm-11-01873"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rostami</surname><given-names>S.</given-names></name>
<name><surname>Kazemi</surname><given-names>A.</given-names></name>
<name><surname>Chahardouli</surname><given-names>B.</given-names></name>
<name><surname>Mohammadi</surname><given-names>S.</given-names></name>
<name><surname>Nikbakht</surname><given-names>M.</given-names></name>
<name><surname>Alizadeh</surname><given-names>N.</given-names></name>
<name><surname>Mousavi</surname><given-names>A.</given-names></name>
<name><surname>Alimoghaddam</surname><given-names>K.</given-names></name>
<name><surname>Ardestani</surname><given-names>M.T.</given-names></name>
</person-group><article-title>The Prognostic Impact of WT1 Expression Levels, Mutations, and SNP rs16754 in AML Patients: A Retrospective Cohort Study</article-title><source>J. Adv. Med. Biomed. Res.</source><year>2021</year><volume>29</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.30699/jambs.29.133.109</pub-id></element-citation></ref><ref id="B4-jcm-11-01873"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sugiyama</surname><given-names>H.</given-names></name>
</person-group><article-title>Wilms&#x02019; tumor gene WT1: Its oncogenic function and clinical application</article-title><source>Int. J. Hematol.</source><year>2001</year><volume>73</volume><fpage>177</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1007/BF02981935</pub-id><pub-id pub-id-type="pmid">11372729</pub-id></element-citation></ref><ref id="B5-jcm-11-01873"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x000f6;hner</surname><given-names>H.</given-names></name>
<name><surname>Weisdorf</surname><given-names>D.J.</given-names></name>
<name><surname>Bloomfield</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Acute Myeloid Leukemia</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>1136</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1406184</pub-id><pub-id pub-id-type="pmid">26376137</pub-id></element-citation></ref><ref id="B6-jcm-11-01873"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>H.J.</given-names></name>
<name><surname>Park</surname><given-names>J.H.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Kang</surname><given-names>S.I.</given-names></name>
<name><surname>Moroz</surname><given-names>K.</given-names></name>
<name><surname>Ladanyi</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>S.B.</given-names></name>
</person-group><article-title>EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>4526</fpage><lpage>4535</lpage><pub-id pub-id-type="doi">10.1158/0008-5472</pub-id><pub-id pub-id-type="pmid">24934812</pub-id></element-citation></ref><ref id="B7-jcm-11-01873"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rampal</surname><given-names>R.</given-names></name>
<name><surname>Figueroa</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia</article-title><source>Haematologica</source><year>2016</year><volume>101</volume><fpage>672</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.3324/haematol.2015.141796</pub-id><pub-id pub-id-type="pmid">27252512</pub-id></element-citation></ref><ref id="B8-jcm-11-01873"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.-H.</given-names></name>
<name><surname>Hur</surname><given-names>E.-H.</given-names></name>
<name><surname>Kang</surname><given-names>M.J.</given-names></name>
<name><surname>Kim</surname><given-names>S.-D.</given-names></name>
<name><surname>Lee</surname><given-names>J.-H.</given-names></name>
<name><surname>Kim</surname><given-names>D.-Y.</given-names></name>
<name><surname>Lim</surname><given-names>S.-N.</given-names></name>
<name><surname>Bae</surname><given-names>K.-S.</given-names></name>
<name><surname>Lim</surname><given-names>H.-S.</given-names></name>
<etal/>
</person-group><article-title>Single nucleotide polymorphism of Wilms&#x02019; tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia</article-title><source>Ann. Hematol.</source><year>2011</year><volume>91</volume><fpage>671</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1007/s00277-011-1355-4</pub-id><pub-id pub-id-type="pmid">22015946</pub-id></element-citation></ref><ref id="B9-jcm-11-01873"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Long</surname><given-names>J.</given-names></name>
<name><surname>Fang</surname><given-names>S.</given-names></name>
<name><surname>Dai</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
</person-group><article-title>The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): A meta-analysis</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>32079</fpage><lpage>32087</lpage><pub-id pub-id-type="pmid">26992216</pub-id></element-citation></ref><ref id="B10-jcm-11-01873"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damm</surname><given-names>F.</given-names></name>
<name><surname>Heuser</surname><given-names>M.</given-names></name>
<name><surname>Morgan</surname><given-names>M.</given-names></name>
<name><surname>Yun</surname><given-names>H.</given-names></name>
<name><surname>Gro&#x000df;hennig</surname><given-names>A.</given-names></name>
<name><surname>G&#x000f6;hring</surname><given-names>G.</given-names></name>
<name><surname>Schlegelberger</surname><given-names>B.</given-names></name>
<name><surname>D&#x000f6;hner</surname><given-names>K.</given-names></name>
<name><surname>Ottmann</surname><given-names>O.</given-names></name>
<name><surname>L&#x000fc;bbert</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>578</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.0342</pub-id><pub-id pub-id-type="pmid">20038731</pub-id></element-citation></ref><ref id="B11-jcm-11-01873"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>J.M.</given-names></name>
<name><surname>Catovsky</surname><given-names>D.</given-names></name>
<name><surname>Daniel</surname><given-names>M.-T.</given-names></name>
<name><surname>Flandrin</surname><given-names>G.</given-names></name>
<name><surname>Galton</surname><given-names>D.A.G.</given-names></name>
<name><surname>Gralnick</surname><given-names>H.R.</given-names></name>
<name><surname>Sultan</surname><given-names>C.</given-names></name>
</person-group><article-title>Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group</article-title><source>Br. J. Haematol.</source><year>1976</year><volume>33</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.1976.tb03563.x</pub-id><pub-id pub-id-type="pmid">188440</pub-id></element-citation></ref><ref id="B12-jcm-11-01873"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>King-Underwood</surname><given-names>L.</given-names></name>
<name><surname>Renshaw</surname><given-names>J.</given-names></name>
<name><surname>Pritchard-Jones</surname><given-names>K.</given-names></name>
</person-group><article-title>Mutations in the Wilms&#x02019; tumor gene WT1 in leukemias</article-title><source>Blood</source><year>1996</year><volume>87</volume><fpage>2171</fpage><lpage>2179</lpage><pub-id pub-id-type="doi">10.1182/blood.V87.6.2171.bloodjournal8762171</pub-id><pub-id pub-id-type="pmid">8630376</pub-id></element-citation></ref><ref id="B13-jcm-11-01873"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andersson</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Lorenz</surname><given-names>F.</given-names></name>
<name><surname>Golovleva</surname><given-names>I.</given-names></name>
<name><surname>Wahlin</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>A.</given-names></name>
</person-group><article-title>Reduction in WT1 Gene Expression During Early Treatment Predicts the Outcome in Patients With Acute Myeloid Leukemia</article-title><source>Diagn. Mol. Pathol.</source><year>2012</year><volume>21</volume><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1097/PDM.0b013e318257ddb9</pub-id><pub-id pub-id-type="pmid">23111196</pub-id></element-citation></ref><ref id="B14-jcm-11-01873"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>K.</given-names></name>
<name><surname>Yan</surname><given-names>Q.-X.</given-names></name>
<name><surname>Shen</surname><given-names>Z.-J.</given-names></name>
<name><surname>Wu</surname><given-names>J.-B.</given-names></name>
<name><surname>Chen</surname><given-names>H.-M.</given-names></name>
<name><surname>Gao</surname><given-names>S.-M.</given-names></name>
</person-group><article-title>Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 inde novonon-M3 acute myeloid leukemia</article-title><source>Leuk. Lymphoma</source><year>2013</year><volume>55</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.3109/10428194.2013.791985</pub-id><pub-id pub-id-type="pmid">23550990</pub-id></element-citation></ref><ref id="B15-jcm-11-01873"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Green</surname><given-names>C.L.</given-names></name>
<name><surname>Koo</surname><given-names>K.K.</given-names></name>
<name><surname>Hills</surname><given-names>R.</given-names></name>
<name><surname>Burnett</surname><given-names>A.K.</given-names></name>
<name><surname>Linch</surname><given-names>D.C.</given-names></name>
<name><surname>Gale</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>2739</fpage><lpage>2747</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.26.2501</pub-id><pub-id pub-id-type="pmid">20439648</pub-id></element-citation></ref><ref id="B16-jcm-11-01873"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paschka</surname><given-names>P.</given-names></name>
<name><surname>Marcucci</surname><given-names>G.</given-names></name>
<name><surname>Ruppert</surname><given-names>A.S.</given-names></name>
<name><surname>Whitman</surname><given-names>S.P.</given-names></name>
<name><surname>Mr&#x000f3;zek</surname><given-names>K.</given-names></name>
<name><surname>Maharry</surname><given-names>K.</given-names></name>
<name><surname>Langer</surname><given-names>C.</given-names></name>
<name><surname>Baldus</surname><given-names>C.D.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Powell</surname><given-names>B.L.</given-names></name>
<etal/>
</person-group><article-title>Wilms&#x02019; Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study</article-title><source>J. Clin. Oncol.</source><year>2008</year><volume>26</volume><fpage>4595</fpage><lpage>4602</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.2058</pub-id><pub-id pub-id-type="pmid">18559874</pub-id></element-citation></ref><ref id="B17-jcm-11-01873"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marcucci</surname><given-names>G.</given-names></name>
<name><surname>Mr&#x000f3;zek</surname><given-names>K.</given-names></name>
<name><surname>Ruppert</surname><given-names>A.S.</given-names></name>
<name><surname>Archer</surname><given-names>K.J.</given-names></name>
<name><surname>Pettenati</surname><given-names>M.J.</given-names></name>
<name><surname>Heerema</surname><given-names>N.A.</given-names></name>
<name><surname>Carroll</surname><given-names>A.J.</given-names></name>
<name><surname>Koduru</surname><given-names>P.R.</given-names></name>
<name><surname>Kolitz</surname><given-names>J.E.</given-names></name>
<name><surname>Sterling</surname><given-names>L.J.</given-names></name>
<etal/>
</person-group><article-title>Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461</article-title><source>J. Clin. Oncol.</source><year>2004</year><volume>22</volume><fpage>2410</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.03.023</pub-id><pub-id pub-id-type="pmid">15197203</pub-id></element-citation></ref><ref id="B18-jcm-11-01873"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Betz</surname><given-names>B.L.</given-names></name>
<name><surname>Hess</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Acute Myeloid Leukemia Diagnosis in the 21st Century</article-title><source>Arch. Pathol. Lab. Med.</source><year>2010</year><volume>134</volume><fpage>1427</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.5858/2010-0245-RA.1</pub-id><pub-id pub-id-type="pmid">20923295</pub-id></element-citation></ref><ref id="B19-jcm-11-01873"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grimwade</surname><given-names>D.</given-names></name>
<name><surname>Walker</surname><given-names>H.</given-names></name>
<name><surname>Oliver</surname><given-names>F.</given-names></name>
<name><surname>Wheatley</surname><given-names>K.</given-names></name>
<name><surname>Harrison</surname><given-names>C.</given-names></name>
<name><surname>Harrison</surname><given-names>G.</given-names></name>
<name><surname>Rees</surname><given-names>J.</given-names></name>
<name><surname>Hann</surname><given-names>I.</given-names></name>
<name><surname>Stevens</surname><given-names>R.</given-names></name>
<name><surname>Burnett</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children&#x02019;s Leukaemia Working Parties</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>2322</fpage><lpage>2333</lpage><comment>Available online: <ext-link xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/9746770" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/pubmed/9746770</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-02-10">(accessed on 10 February 2022)</date-in-citation><pub-id pub-id-type="doi">10.1182/blood.V92.7.2322</pub-id><pub-id pub-id-type="pmid">9746770</pub-id></element-citation></ref><ref id="B20-jcm-11-01873"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x000f6;hner</surname><given-names>H.</given-names></name>
<name><surname>Estey</surname><given-names>E.H.</given-names></name>
<name><surname>Amadori</surname><given-names>S.</given-names></name>
<name><surname>Appelbaum</surname><given-names>F.R.</given-names></name>
<name><surname>B&#x000fc;chner</surname><given-names>T.</given-names></name>
<name><surname>Burnett</surname><given-names>A.K.</given-names></name>
<name><surname>Dombret</surname><given-names>H.</given-names></name>
<name><surname>Fenaux</surname><given-names>P.</given-names></name>
<name><surname>Grimwade</surname><given-names>D.</given-names></name>
<name><surname>Larson</surname><given-names>R.A.</given-names></name>
<etal/>
</person-group><article-title>Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>453</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-07-235358</pub-id><pub-id pub-id-type="pmid">19880497</pub-id></element-citation></ref><ref id="B21-jcm-11-01873"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Summers</surname><given-names>K.</given-names></name>
<name><surname>Stevens</surname><given-names>J.</given-names></name>
<name><surname>Kakkas</surname><given-names>I.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Smith</surname><given-names>L.L.</given-names></name>
<name><surname>MacDougall</surname><given-names>F.</given-names></name>
<name><surname>Cavenagh</surname><given-names>J.</given-names></name>
<name><surname>Bonnet</surname><given-names>D.</given-names></name>
<name><surname>Young</surname><given-names>B.D.</given-names></name>
<name><surname>Lister</surname><given-names>T.A.</given-names></name>
<etal/>
</person-group><article-title>Wilms&#x02019; tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>550</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404514</pub-id><pub-id pub-id-type="pmid">17205055</pub-id></element-citation></ref><ref id="B22-jcm-11-01873"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chomczynski</surname><given-names>P.</given-names></name>
<name><surname>Sacchi</surname><given-names>N.</given-names></name>
</person-group><article-title>Single-step method of RNA isolation by acid guanidinium thiocyanate&#x02013;phenol&#x02013;chloroform extraction</article-title><source>Anal. Biochem.</source><year>1987</year><volume>162</volume><fpage>156</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(87)90021-2</pub-id><pub-id pub-id-type="pmid">2440339</pub-id></element-citation></ref><ref id="B23-jcm-11-01873"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cilloni</surname><given-names>D.</given-names></name>
<name><surname>Gottardi</surname><given-names>E.</given-names></name>
<name><surname>De Micheli</surname><given-names>D.</given-names></name>
<name><surname>Serra</surname><given-names>A.</given-names></name>
<name><surname>Volpe</surname><given-names>G.</given-names></name>
<name><surname>Messa</surname><given-names>F.</given-names></name>
<name><surname>Rege-Cambrin</surname><given-names>G.</given-names></name>
<name><surname>Guerrasio</surname><given-names>A.</given-names></name>
<name><surname>Divona</surname><given-names>M.</given-names></name>
<name><surname>Coco</surname><given-names>F.L.</given-names></name>
<etal/>
</person-group><article-title>Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients</article-title><source>Leukemia</source><year>2002</year><volume>16</volume><fpage>2115</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402675</pub-id><pub-id pub-id-type="pmid">12357365</pub-id></element-citation></ref><ref id="B24-jcm-11-01873"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beillard</surname><given-names>E.</given-names></name>
<name><surname>Pallisgaard</surname><given-names>N.</given-names></name>
<name><surname>Van Der Velden</surname><given-names>V.H.J.</given-names></name>
<name><surname>Bi</surname><given-names>W.</given-names></name>
<name><surname>Dee</surname><given-names>R.</given-names></name>
<name><surname>Van Der Schoot</surname><given-names>E.</given-names></name>
<name><surname>Delabesse</surname><given-names>E.</given-names></name>
<name><surname>MacIntyre</surname><given-names>E.</given-names></name>
<name><surname>Gottardi</surname><given-names>E.</given-names></name>
<name><surname>Saglio</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using &#x02018;real-time&#x02019; quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)&#x02014;A Europe against cancer program</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>2474</fpage><lpage>2486</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2403136</pub-id><pub-id pub-id-type="pmid">14562124</pub-id></element-citation></ref><ref id="B25-jcm-11-01873"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Marchi</surname><given-names>F.</given-names></name>
<name><surname>Candoni</surname><given-names>A.</given-names></name>
<name><surname>Zannier</surname><given-names>M.E.</given-names></name>
<name><surname>Haley</surname><given-names>L.</given-names></name>
<name><surname>Lau</surname><given-names>B.W.Y.</given-names></name>
<name><surname>Fanin</surname><given-names>R.</given-names></name>
</person-group><article-title>Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: Which should we trust as a minimal residual disease marker?</article-title><source>Am. J. Hematol.</source><year>2017</year><volume>92</volume><fpage>E72</fpage><lpage>E74</lpage><pub-id pub-id-type="doi">10.1002/ajh.24686</pub-id><pub-id pub-id-type="pmid">28211167</pub-id></element-citation></ref><ref id="B26-jcm-11-01873"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koczkodaj</surname><given-names>D.</given-names></name>
<name><surname>Zmorzy&#x00144;ski</surname><given-names>S.</given-names></name>
<name><surname>Michalak-Wojnowska</surname><given-names>M.</given-names></name>
<name><surname>Wasik-Szczepanek</surname><given-names>E.</given-names></name>
<name><surname>Filip</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland</article-title><source>Arch. Med Sci.</source><year>2016</year><volume>1</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.5114/aoms.2015.49811</pub-id><pub-id pub-id-type="pmid">26925127</pub-id></element-citation></ref><ref id="B27-jcm-11-01873"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benthaus</surname><given-names>T.</given-names></name>
<name><surname>Schneider</surname><given-names>F.</given-names></name>
<name><surname>Mellert</surname><given-names>G.</given-names></name>
<name><surname>Zellmeier</surname><given-names>E.</given-names></name>
<name><surname>Schneider</surname><given-names>S.</given-names></name>
<name><surname>Kakadia</surname><given-names>P.M.</given-names></name>
<name><surname>Hiddemann</surname><given-names>W.</given-names></name>
<name><surname>Bohlander</surname><given-names>S.</given-names></name>
<name><surname>Feuring-Buske</surname><given-names>M.</given-names></name>
<name><surname>Braess</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Rapid and sensitive screening forCEBPAmutations in acute myeloid leukaemia</article-title><source>Br. J. Haematol.</source><year>2008</year><volume>143</volume><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07328.x</pub-id><pub-id pub-id-type="pmid">18752591</pub-id></element-citation></ref><ref id="B28-jcm-11-01873"><label>28.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Preacher</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Calculation for the Chi-Square Test: An Interactive Calculation Tool for Chi-Square Tests of Goodness of Fit and Independence</article-title><year>2019</year><comment>Available online: <ext-link xlink:href="http://quantpsy.org/" ext-link-type="uri">http://quantpsy.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-01-21">(accessed on 21 January 2022)</date-in-citation></element-citation></ref><ref id="B29-jcm-11-01873"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zmorzynski</surname><given-names>S.</given-names></name>
<name><surname>Szudy-Szczyrek</surname><given-names>A.</given-names></name>
<name><surname>Popek-Marciniec</surname><given-names>S.</given-names></name>
<name><surname>Korszen-Pilecka</surname><given-names>I.</given-names></name>
<name><surname>Wojcierowska-Litwin</surname><given-names>M.</given-names></name>
<name><surname>Luterek</surname><given-names>M.</given-names></name>
<name><surname>Chocholska</surname><given-names>S.</given-names></name>
<name><surname>Styk</surname><given-names>W.</given-names></name>
<name><surname>Swiderska-Ko&#x00142;acz</surname><given-names>G.</given-names></name>
<name><surname>Januszewska</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00044</pub-id><pub-id pub-id-type="pmid">30788288</pub-id></element-citation></ref><ref id="B30-jcm-11-01873"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.</given-names></name>
<name><surname>Kim</surname><given-names>I.-S.</given-names></name>
<name><surname>Chang</surname><given-names>C.L.</given-names></name>
<name><surname>Kang</surname><given-names>J.-E.</given-names></name>
<name><surname>Lee</surname><given-names>E.Y.</given-names></name>
<name><surname>Shin</surname><given-names>H.-J.</given-names></name>
</person-group><article-title>Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm</article-title><source>Ann. Lab. Med.</source><year>2015</year><volume>35</volume><fpage>348</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.3343/alm.2015.35.3.348</pub-id><pub-id pub-id-type="pmid">25932444</pub-id></element-citation></ref><ref id="B31-jcm-11-01873"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>D.-Y.</given-names></name>
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>X.-L.</given-names></name>
<name><surname>Zeng</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.-P.</given-names></name>
</person-group><article-title>Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population</article-title><source>Leuk. Res.</source><year>2015</year><volume>39</volume><fpage>568</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2015.03.005</pub-id><pub-id pub-id-type="pmid">25841655</pub-id></element-citation></ref><ref id="B32-jcm-11-01873"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krauth</surname><given-names>M.-T.</given-names></name>
<name><surname>Alpermann</surname><given-names>T.</given-names></name>
<name><surname>Bacher</surname><given-names>U.</given-names></name>
<name><surname>Eder</surname><given-names>C.</given-names></name>
<name><surname>Dicker</surname><given-names>F.</given-names></name>
<name><surname>Ulke</surname><given-names>M.</given-names></name>
<name><surname>Kuznia</surname><given-names>S.</given-names></name>
<name><surname>Nadarajah</surname><given-names>N.</given-names></name>
<name><surname>Kern</surname><given-names>W.</given-names></name>
<name><surname>Haferlach</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups</article-title><source>Leukemia</source><year>2014</year><volume>29</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1038/leu.2014.243</pub-id><pub-id pub-id-type="pmid">25110071</pub-id></element-citation></ref><ref id="B33-jcm-11-01873"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaidzik</surname><given-names>V.I.</given-names></name>
<name><surname>Schlenk</surname><given-names>R.F.</given-names></name>
<name><surname>Moschny</surname><given-names>S.</given-names></name>
<name><surname>Becker</surname><given-names>A.</given-names></name>
<name><surname>Bullinger</surname><given-names>L.</given-names></name>
<name><surname>Corbacioglu</surname><given-names>A.</given-names></name>
<name><surname>Krauter</surname><given-names>J.</given-names></name>
<name><surname>Schlegelberger</surname><given-names>B.</given-names></name>
<name><surname>Ganser</surname><given-names>A.</given-names></name>
<name><surname>D&#x000f6;hner</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: A study of the German-Austrian AML Study Group</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>4505</fpage><lpage>4511</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-10-183392</pub-id><pub-id pub-id-type="pmid">19221039</pub-id></element-citation></ref><ref id="B34-jcm-11-01873"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>H.-A.</given-names></name>
<name><surname>Huang</surname><given-names>T.-C.</given-names></name>
<name><surname>Lin</surname><given-names>L.-I.</given-names></name>
<name><surname>Liu</surname><given-names>C.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>C.-Y.</given-names></name>
<name><surname>Chou</surname><given-names>W.-C.</given-names></name>
<name><surname>Tang</surname><given-names>J.-L.</given-names></name>
<name><surname>Tseng</surname><given-names>M.-H.</given-names></name>
<name><surname>Huang</surname><given-names>C.-F.</given-names></name>
<name><surname>Chiang</surname><given-names>Y.-C.</given-names></name>
<etal/>
</person-group><article-title>WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>5222</fpage><lpage>5231</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-12-259390</pub-id><pub-id pub-id-type="pmid">20368469</pub-id></element-citation></ref><ref id="B35-jcm-11-01873"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toogeh</surname><given-names>G.</given-names></name>
<name><surname>Ramzi</surname><given-names>M.</given-names></name>
<name><surname>Faranoush</surname><given-names>M.</given-names></name>
<name><surname>Amirizadeh</surname><given-names>N.</given-names></name>
<name><surname>Haghpanah</surname><given-names>S.</given-names></name>
<name><surname>Moghadam</surname><given-names>M.</given-names></name>
<name><surname>Cohan</surname><given-names>N.</given-names></name>
</person-group><article-title>Prevalence and Prognostic Impact of Wilms&#x02019; Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience</article-title><source>Clin. Lymphoma Myeloma Leuk.</source><year>2016</year><volume>16</volume><fpage>e21</fpage><lpage>e26</lpage><pub-id pub-id-type="doi">10.1016/j.clml.2015.11.017</pub-id><pub-id pub-id-type="pmid">26725263</pub-id></element-citation></ref><ref id="B36-jcm-11-01873"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
</person-group><article-title>Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: An analysis based on TCGA database</article-title><source>Hematology</source><year>2020</year><volume>25</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1080/16078454.2020.1720102</pub-id><pub-id pub-id-type="pmid">32019476</pub-id></element-citation></ref><ref id="B37-jcm-11-01873"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niktoreh</surname><given-names>N.</given-names></name>
<name><surname>Walter</surname><given-names>C.</given-names></name>
<name><surname>Zimmermann</surname><given-names>M.</given-names></name>
<name><surname>von Neuhoff</surname><given-names>C.</given-names></name>
<name><surname>von Neuhoff</surname><given-names>N.</given-names></name>
<name><surname>Rasche</surname><given-names>M.</given-names></name>
<name><surname>Waack</surname><given-names>K.</given-names></name>
<name><surname>Creutzig</surname><given-names>U.</given-names></name>
<name><surname>Hanenberg</surname><given-names>H.</given-names></name>
<name><surname>Reinhardt</surname><given-names>D.</given-names></name>
</person-group><article-title>Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia</article-title><source>J. Oncol.</source><year>2019</year><volume>2019</volume><fpage>1609128</fpage><pub-id pub-id-type="doi">10.1155/2019/1609128</pub-id><pub-id pub-id-type="pmid">31467532</pub-id></element-citation></ref><ref id="B38-jcm-11-01873"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Stasi</surname><given-names>A.</given-names></name>
<name><surname>Jimenez</surname><given-names>A.M.</given-names></name>
<name><surname>Eminagawa</surname><given-names>K.</given-names></name>
<name><surname>Eal-Obaidi</surname><given-names>M.</given-names></name>
<name><surname>Erezvani</surname><given-names>K.</given-names></name>
</person-group><article-title>Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies</article-title><source>Front. Immunol.</source><year>2015</year><volume>6</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00036</pub-id><pub-id pub-id-type="pmid">25699052</pub-id></element-citation></ref><ref id="B39-jcm-11-01873"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>J.-H.</given-names></name>
<name><surname>Kim</surname><given-names>H.-J.</given-names></name>
<name><surname>Shin</surname><given-names>S.-H.</given-names></name>
<name><surname>Yahng</surname><given-names>S.-A.</given-names></name>
<name><surname>Lee</surname><given-names>S.-E.</given-names></name>
<name><surname>Cho</surname><given-names>B.-S.</given-names></name>
<name><surname>Eom</surname><given-names>K.-S.</given-names></name>
<name><surname>Kim</surname><given-names>Y.-J.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Min</surname><given-names>C.-K.</given-names></name>
<etal/>
</person-group><article-title>Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically Normal Acute Myelogenous Leukemia</article-title><source>Biol. Blood Marrow Transplant.</source><year>2013</year><volume>19</volume><fpage>958</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2013.03.013</pub-id><pub-id pub-id-type="pmid">23542687</pub-id></element-citation></ref><ref id="B40-jcm-11-01873"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimada</surname><given-names>A.</given-names></name>
<name><surname>Taki</surname><given-names>T.</given-names></name>
<name><surname>Koga</surname><given-names>D.</given-names></name>
<name><surname>Tabuchi</surname><given-names>K.</given-names></name>
<name><surname>Tawa</surname><given-names>A.</given-names></name>
<name><surname>Hanada</surname><given-names>R.</given-names></name>
<name><surname>Tsuchida</surname><given-names>M.</given-names></name>
<name><surname>Horibe</surname><given-names>K.</given-names></name>
<name><surname>Tsukimoto</surname><given-names>I.</given-names></name>
<name><surname>Adachi</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: A study of the Japanese Childhood AML Cooperative Study Group</article-title><source>Int. J. Hematol.</source><year>2012</year><volume>96</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1007/s12185-012-1163-1</pub-id><pub-id pub-id-type="pmid">22915059</pub-id></element-citation></ref><ref id="B41-jcm-11-01873"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suela</surname><given-names>J.</given-names></name>
<name><surname>Alvarez</surname><given-names>S.</given-names></name>
<name><surname>Cigudosa</surname><given-names>J.</given-names></name>
</person-group><article-title>DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes</article-title><source>Cytogenet. Genome Res.</source><year>2007</year><volume>118</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1159/000108314</pub-id><pub-id pub-id-type="pmid">18000384</pub-id></element-citation></ref><ref id="B42-jcm-11-01873"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Evers</surname><given-names>C.</given-names></name>
<name><surname>Beier</surname><given-names>M.</given-names></name>
<name><surname>Poelitz</surname><given-names>A.</given-names></name>
<name><surname>Hildebrandt</surname><given-names>B.</given-names></name>
<name><surname>Servan</surname><given-names>K.</given-names></name>
<name><surname>Drechsler</surname><given-names>M.</given-names></name>
<name><surname>Germing</surname><given-names>U.</given-names></name>
<name><surname>Royer</surname><given-names>H.-D.</given-names></name>
<name><surname>Royer-Pokora</surname><given-names>B.</given-names></name>
</person-group><article-title>Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH</article-title><source>Genes Chromosom. Cancer</source><year>2007</year><volume>46</volume><fpage>1119</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1002/gcc.20498</pub-id><pub-id pub-id-type="pmid">17823930</pub-id></element-citation></ref><ref id="B43-jcm-11-01873"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>R&#x000fc;cker</surname><given-names>F.G.</given-names></name>
<name><surname>Bullinger</surname><given-names>L.</given-names></name>
<name><surname>Schwaenen</surname><given-names>C.</given-names></name>
<name><surname>Lipka</surname><given-names>D.B.</given-names></name>
<name><surname>Wessendorf</surname><given-names>S.</given-names></name>
<name><surname>Fr&#x000f6;hling</surname><given-names>S.</given-names></name>
<name><surname>Bentz</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>S.</given-names></name>
<name><surname>Scholl</surname><given-names>C.</given-names></name>
<name><surname>Schlenk</surname><given-names>R.F.</given-names></name>
<etal/>
</person-group><article-title>Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization</article-title><source>J. Clin. Oncol.</source><year>2006</year><volume>24</volume><fpage>3887</fpage><lpage>3894</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.5450</pub-id><pub-id pub-id-type="pmid">16864856</pub-id></element-citation></ref><ref id="B44-jcm-11-01873"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.R.S.</given-names></name>
<name><surname>Belangero</surname><given-names>S.</given-names></name>
<name><surname>Melaragno</surname><given-names>M.I.</given-names></name>
<name><surname>Chauffaille</surname><given-names>M.D.L.</given-names></name>
</person-group><article-title>Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML</article-title><source>Med. Oncol.</source><year>2012</year><volume>29</volume><fpage>2083</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1007/s12032-011-0108-5</pub-id><pub-id pub-id-type="pmid">22116774</pub-id></element-citation></ref><ref id="B45-jcm-11-01873"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehrotra</surname><given-names>M.</given-names></name>
<name><surname>Luthra</surname><given-names>R.</given-names></name>
<name><surname>Ravandi</surname><given-names>F.</given-names></name>
<name><surname>Sargent</surname><given-names>R.L.</given-names></name>
<name><surname>Barkoh</surname><given-names>B.A.</given-names></name>
<name><surname>Abraham</surname><given-names>R.</given-names></name>
<name><surname>Mishra</surname><given-names>B.M.</given-names></name>
<name><surname>Medeiros</surname><given-names>L.J.</given-names></name>
<name><surname>Patel</surname><given-names>K.P.</given-names></name>
</person-group><article-title>Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization</article-title><source>Leuk. Lymphoma</source><year>2014</year><volume>55</volume><fpage>2538</fpage><lpage>2548</lpage><pub-id pub-id-type="doi">10.3109/10428194.2014.883073</pub-id><pub-id pub-id-type="pmid">24446873</pub-id></element-citation></ref><ref id="B46-jcm-11-01873"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Veigaard</surname><given-names>C.</given-names></name>
<name><surname>N&#x000f8;rgaard</surname><given-names>J.M.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>E.</given-names></name>
</person-group><article-title>Genomic profiling in high hyperdiploid acute myeloid leukemia: A retrospective study of 19 cases</article-title><source>Cancer Genet.</source><year>2011</year><volume>204</volume><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2011.09.002</pub-id><pub-id pub-id-type="pmid">22018275</pub-id></element-citation></ref><ref id="B47-jcm-11-01873"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schoch</surname><given-names>C.</given-names></name>
<name><surname>Kern</surname><given-names>W.</given-names></name>
<name><surname>Kohlmann</surname><given-names>A.</given-names></name>
<name><surname>Hiddemann</surname><given-names>W.</given-names></name>
<name><surname>Schnittger</surname><given-names>S.</given-names></name>
<name><surname>Haferlach</surname><given-names>T.</given-names></name>
</person-group><article-title>Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile</article-title><source>Genes Chromosom. Cancer</source><year>2005</year><volume>43</volume><fpage>227</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1002/gcc.20193</pub-id><pub-id pub-id-type="pmid">15846790</pub-id></element-citation></ref><ref id="B48-jcm-11-01873"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Itzhar</surname><given-names>N.</given-names></name>
<name><surname>Dessen</surname><given-names>P.</given-names></name>
<name><surname>Toujani</surname><given-names>S.</given-names></name>
<name><surname>Auger</surname><given-names>N.</given-names></name>
<name><surname>Preudhomme</surname><given-names>C.</given-names></name>
<name><surname>Richon</surname><given-names>C.</given-names></name>
<name><surname>Lazar</surname><given-names>V.</given-names></name>
<name><surname>Saada</surname><given-names>V.</given-names></name>
<name><surname>Bennaceur</surname><given-names>A.</given-names></name>
<name><surname>Bourhis</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Chromosomal Minimal Critical Regions in Therapy-Related Leukemia Appear Different from Those of De Novo Leukemia by High-Resolution aCGH</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e16623</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0016623</pub-id><pub-id pub-id-type="pmid">21339820</pub-id></element-citation></ref><ref id="B49-jcm-11-01873"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thiede</surname><given-names>C.</given-names></name>
<name><surname>Steudel</surname><given-names>C.</given-names></name>
<name><surname>Mohr</surname><given-names>B.</given-names></name>
<name><surname>Schaich</surname><given-names>M.</given-names></name>
<name><surname>Sch&#x000e4;kel</surname><given-names>U.</given-names></name>
<name><surname>Platzbecker</surname><given-names>U.</given-names></name>
<name><surname>Wermke</surname><given-names>M.</given-names></name>
<name><surname>Bornh&#x000e4;user</surname><given-names>M.</given-names></name>
<name><surname>Ritter</surname><given-names>M.</given-names></name>
<name><surname>Neubauer</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>4326</fpage><lpage>4335</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.12.4326</pub-id><pub-id pub-id-type="pmid">12036858</pub-id></element-citation></ref><ref id="B50-jcm-11-01873"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>B.</given-names></name>
<name><surname>Chi</surname><given-names>H.-S.</given-names></name>
<name><surname>Park</surname><given-names>S.-J.</given-names></name>
<name><surname>Min</surname><given-names>S.K.</given-names></name>
<name><surname>Jang</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>C.-J.</given-names></name>
<name><surname>Kim</surname><given-names>D.-Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.-H.</given-names></name>
<name><surname>Lee</surname><given-names>J.-H.</given-names></name>
<name><surname>Lee</surname><given-names>K.-H.</given-names></name>
</person-group><article-title>Clinical Implications of Non-A-Type NPM1 and FLT3 Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia</article-title><source>Acta Haematol.</source><year>2012</year><volume>127</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1159/000331509</pub-id><pub-id pub-id-type="pmid">22104247</pub-id></element-citation></ref><ref id="B51-jcm-11-01873"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mr&#x000f3;zek</surname><given-names>K.</given-names></name>
<name><surname>Marcucci</surname><given-names>G.</given-names></name>
<name><surname>Paschka</surname><given-names>P.</given-names></name>
<name><surname>Bloomfield</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia</article-title><source>Curr. Opin. Oncol.</source><year>2008</year><volume>20</volume><fpage>711</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1097/CCO.0b013e32831369df</pub-id><pub-id pub-id-type="pmid">18841055</pub-id></element-citation></ref><ref id="B52-jcm-11-01873"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fr&#x000f6;hling</surname><given-names>S.</given-names></name>
<name><surname>Schlenk</surname><given-names>R.F.</given-names></name>
<name><surname>Breitruck</surname><given-names>J.</given-names></name>
<name><surname>Benner</surname><given-names>A.</given-names></name>
<name><surname>Kreitmeier</surname><given-names>S.</given-names></name>
<name><surname>Tobis</surname><given-names>K.</given-names></name>
<name><surname>Do&#x000f6;hner</surname><given-names>H.</given-names></name>
<name><surname>Do&#x000f6;hner</surname><given-names>K.</given-names></name>
</person-group><article-title>Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>4372</fpage><lpage>4380</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-05-1440</pub-id><pub-id pub-id-type="pmid">12393388</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-11-01873-f001"><label>Figure 1</label><caption><p>Kaplan&#x02013;Meier analysis of OS in the group of AML patients taking into account: (<bold>a</bold>) <italic toggle="yes">WT1</italic> mutation; (<bold>b</bold>) <italic toggle="yes">WT1</italic> rs16754 variant; (<bold>c</bold>) <italic toggle="yes">WT1</italic> overexpression.</p></caption><graphic xlink:href="jcm-11-01873-g001" position="float"/></fig><fig position="float" id="jcm-11-01873-f002"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier analysis of RFS in the group of AML patients taking into account: (<bold>a</bold>) <italic toggle="yes">WT1</italic> mutation; (<bold>b</bold>) <italic toggle="yes">WT1</italic> rs16754 variant; (<bold>c</bold>) <italic toggle="yes">WT1</italic> overexpression.</p></caption><graphic xlink:href="jcm-11-01873-g002" position="float"/></fig><table-wrap position="float" id="jcm-11-01873-t001"><object-id pub-id-type="pii">jcm-11-01873-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical-laboratory characteristics of patients with AML.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age median (range)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">62.63 (18&#x02013;85)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42 (47)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (53)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laboratory parameters (range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HB g/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.26 (4.8&#x02013;9.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WBC G/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.15 (0.8&#x02013;94.84)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLT G/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.06 (6.0&#x02013;783.0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FAB subtype:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk category:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">favorable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">intermediate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">adverse</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induction therapy:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idarubicin + ATRA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AZA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">reduced DA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">low-dose cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stem cell transplantation:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">allogeneic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">autologous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytogenetic:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal karyotype</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abnormal karyotype</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (22 *)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FISH (%):</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">del(13)(q14.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51 (56.6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">del(17)(p13.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (16.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">del(11)(q23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (14.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">del(6)(q23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (5.5)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">t(15;17)(q22;q21.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (6.6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">BCR/ABL</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">MLL</italic> amplification</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">MYC</italic> amplification</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">EVI1</italic> amplification</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunophenotype&#x02014;negativity/positivity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51/39</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19/71</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66/24</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Molecular variants&#x02014;present/absent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">FLT3</italic>-ITD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/82</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">NPM1</italic> mutation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/79</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CEBPA</italic> mutation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/83</td></tr></tbody></table><table-wrap-foot><fn><p>* complex karyotype.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-11-01873-t002"><object-id pub-id-type="pii">jcm-11-01873-t002_Table 2</object-id><label>Table 2</label><caption><p>Hardy&#x02013;Weinberg equilibrium (HWE) for <italic toggle="yes">WT1</italic> rs16754 variant in case and control groups according to expected (E) and observed (O) values.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GROUPS</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GENOTYPES</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HWE <italic toggle="yes">p</italic> Value and &#x003c7;<sup>2</sup> *</th></tr></thead><tbody><tr><td colspan="6" align="center" valign="middle" rowspan="1"><italic toggle="yes">WT1</italic> rs16754 variant</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">AA</td><td align="center" valign="middle" rowspan="1" colspan="1">GA</td><td align="center" valign="middle" rowspan="1" colspan="1">GG</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CONTROL</td><td colspan="5" align="center" valign="middle" rowspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">E</td><td align="center" valign="middle" rowspan="1" colspan="1">79.21</td><td align="center" valign="middle" rowspan="1" colspan="1">19.58</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td rowspan="2" align="center" valign="middle" colspan="1"><italic toggle="yes">p</italic> = 0.44, &#x003c7;<sup>2</sup> = 0.57</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">O</td><td align="center" valign="middle" rowspan="1" colspan="1">80</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CASE</td><td colspan="5" align="center" valign="middle" rowspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">E</td><td align="center" valign="middle" rowspan="1" colspan="1">70.2</td><td align="center" valign="middle" rowspan="1" colspan="1">18.55</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic> = 0.0007, &#x003c7;<sup>2</sup> = 11.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr></tbody></table><table-wrap-foot><fn><p>* if the &#x003c7;<sup>2</sup> &#x02264; 3.84 and the corresponding <italic toggle="yes">p</italic> &#x02265; 0.05, then the population is in HWE.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-11-01873-t003"><object-id pub-id-type="pii">jcm-11-01873-t003_Table 3</object-id><label>Table 3</label><caption><p>The comparison of allele frequency and distribution of <italic toggle="yes">WT1</italic> variant among AML patients and controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Variants and Alleles</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AML n (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Controls n (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Odds Ratio</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Values</th></tr></thead><tbody><tr><td colspan="6" align="center" valign="middle" rowspan="1">Codominant model</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AA</td><td align="center" valign="middle" rowspan="1" colspan="1">74 (82.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (80%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GA</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (12.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (18%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67&#x02013;3.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GG</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06&#x02013;1.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41</td></tr><tr><td colspan="6" align="center" valign="middle" rowspan="1">Dominant model</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AA</td><td align="center" valign="middle" rowspan="1" colspan="1">74 (82.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (80%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GA + GG</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (17.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (20%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55&#x02013;2.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69</td></tr><tr><td colspan="6" align="center" valign="middle" rowspan="1">Recessive model</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AA + GA</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (94.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">98 (98%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GG</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06&#x02013;1.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total:</td><td align="center" valign="middle" rowspan="1" colspan="1">90 (100%)</td><td align="center" valign="middle" rowspan="1" colspan="1">100 (100%)</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alleles</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">159 (88.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">178 (89%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (11.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93</td><td align="center" valign="middle" rowspan="1" colspan="1">0.49&#x02013;1.76</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">180 (100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200 (100%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jcm-11-01873-t004"><object-id pub-id-type="pii">jcm-11-01873-t004_Table 4</object-id><label>Table 4</label><caption><p>Correlation of <italic toggle="yes">WT1</italic> variants and overexpression with clinical characteristics in AML patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Features</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> AA Genotype</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> GA + GG Genotype</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> Mutated</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> Wild Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> Expression *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> Expression **</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.61</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age &#x0003c; 65 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.64</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age &#x02265; 65 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytogenetics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal karyotype</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.63</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abnormal karyotype</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Point mutations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">NPM1</italic> wild type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">NPM1</italic> mutated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">FLT3</italic> wild type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">FLT3</italic> mutated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CEBPA</italic> wild type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.74</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CEBPA</italic> mutated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical values</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WBC median</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hb median</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLT median</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">137.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic toggle="yes">WT1</italic> expression lower than medium value (NCN = 13,273.12). ** <italic toggle="yes">WT1</italic> expression higher than medium value (NCN = 13,273.12).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-11-01873-t005"><object-id pub-id-type="pii">jcm-11-01873-t005_Table 5</object-id><label>Table 5</label><caption><p>Analysis of prognostic impact on OS and RFS in AML patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Feature</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Univariate Analysis</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Multivariate Analysis</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td colspan="7" align="center" valign="middle" rowspan="1">OS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">2.52</td><td align="center" valign="middle" rowspan="1" colspan="1">1.33&#x02013;4,81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22&#x02013;0.81</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> mutation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59&#x02013;2.33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48&#x02013;1.52</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> overexpression</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76</td><td align="center" valign="middle" rowspan="1" colspan="1">0.44&#x02013;1.34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45&#x02013;1.82</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">NPM1</italic> mutation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" rowspan="1" colspan="1">2.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81&#x02013;5.10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61&#x02013;4.93</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">FLT3</italic>-ITD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35&#x02013;2.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78</td><td align="center" valign="middle" rowspan="1" colspan="1">0.29&#x02013;1.93</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">CEBPA</italic> mutation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" rowspan="1" colspan="1">1.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45&#x02013;4.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27&#x02013;3.27</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Abnormal karyotype</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53&#x02013;1.47</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51&#x02013;1.56</td></tr><tr><td colspan="7" align="center" valign="middle" rowspan="1">RFS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">2.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92&#x02013;4.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27&#x02013;1.52</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> mutation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" rowspan="1" colspan="1">1.84</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59&#x02013;3.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36&#x02013;2.18</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">WT1</italic> overexpression</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31&#x02013;1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">0.33&#x02013;1.83</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">NPM1</italic> mutation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">3.46</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03&#x02013;6.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">2.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92&#x02013;5.45</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">FLT3</italic>-ITD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">0.26&#x02013;2.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15&#x02013;1.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">CEBPA</italic> mutation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">2.37</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70&#x02013;7.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.62</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.39&#x02013;5.75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abnormal karyotype</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37&#x02013;1.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35&#x02013;1.87</td></tr></tbody></table></table-wrap></floats-group></article>
